Denis Séguier1, Philippe Puech2, Ronald Kool3, Léa Dernis4, Héléna Gabert1, Wassim Kassouf3, Arnauld Villers1, Gautier Marcq5. 1. Urology Department, Claude Huriez Hospital, CHU Lille, Lille, Hauts-de-France, France. 2. Univ. Lille, Inserm, CHU Lille, Department of Radiology, U1189 - ONCO-THAI - Image Assisted Laser Therapy for Oncology, Lille, France. 3. Division of Urology, McGill University Health Centre, McGill University, Montreal, QC, Canada. 4. Department of Radiology, U1189 - ONCO-THAI - Image Assisted Laser Therapy for Oncology, Lille, France. 5. Lille University, School of Medicine, Urology Department, Claude Huriez Hospital, CHRU Lille, LILLE Cedex, France Researcher - PhD Candidate, Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, UMR9020-U1277 - CANTHER - Cancer Heterogeneity Plasticity and Resistance to Therapies, Lille, France.
Abstract
BACKGROUND: The Vesical Imaging-Reporting and Data System (VI-RADS) score is a novel standardized approach to image and report bladder cancer (BC) with multiparametric MRI (mpMRI). OBJECTIVES: To describe and evaluate the performance of the VI-RADS score using mpMRI and assess its potential clinical applications and limitations. METHODS: A systematic review was conducted using the MEDLINE and EMBASE electronic bibliographic databases between June 2020 and December 2020. All reports deemed relevant to describe the VI-RADS score and assess its performance and applications were retrieved. Results presentation stands as narrative, purely descriptive synthesis based on aggregate studies data. RESULTS: A total of 20 relevant studies were retrieved: three meta-analyses, five prospective studies, and twelve retrospective studies. The retrospective studies covered 1676 patients, while the prospective studies included a total number of 468 patients. Pooled sensitivity, specificity to differentiate muscle-invasive from non-muscle-invasive bladder cancer, ranged from 74.1% to 97.3%, and 77% to 100%, respectively. The chosen VI-RADS score thresholds for this discrimination varied across studies. The interreader agreement ranged from 0.73 to 0.95. Currently, the potential clinical applications of VI-RADS consist of initial BC risk stratification, assessment of neoadjuvant therapies response, and bladder sparing approaches, although further validation is required. CONCLUSIONS: The VI-RADS score helps to discriminate muscle invasive from non-muscle invasive BC with good performance and reproducibility. A simple algorithm based on four basic questions may enhance its popularization. Further studies are required to validate the clinical applications.
BACKGROUND: The Vesical Imaging-Reporting and Data System (VI-RADS) score is a novel standardized approach to image and report bladder cancer (BC) with multiparametric MRI (mpMRI). OBJECTIVES: To describe and evaluate the performance of the VI-RADS score using mpMRI and assess its potential clinical applications and limitations. METHODS: A systematic review was conducted using the MEDLINE and EMBASE electronic bibliographic databases between June 2020 and December 2020. All reports deemed relevant to describe the VI-RADS score and assess its performance and applications were retrieved. Results presentation stands as narrative, purely descriptive synthesis based on aggregate studies data. RESULTS: A total of 20 relevant studies were retrieved: three meta-analyses, five prospective studies, and twelve retrospective studies. The retrospective studies covered 1676 patients, while the prospective studies included a total number of 468 patients. Pooled sensitivity, specificity to differentiate muscle-invasive from non-muscle-invasive bladder cancer, ranged from 74.1% to 97.3%, and 77% to 100%, respectively. The chosen VI-RADS score thresholds for this discrimination varied across studies. The interreader agreement ranged from 0.73 to 0.95. Currently, the potential clinical applications of VI-RADS consist of initial BC risk stratification, assessment of neoadjuvant therapies response, and bladder sparing approaches, although further validation is required. CONCLUSIONS: The VI-RADS score helps to discriminate muscle invasive from non-muscle invasive BC with good performance and reproducibility. A simple algorithm based on four basic questions may enhance its popularization. Further studies are required to validate the clinical applications.
Authors: H Barton Grossman; Ronald B Natale; Catherine M Tangen; V O Speights; Nicholas J Vogelzang; Donald L Trump; Ralph W deVere White; Michael F Sarosdy; David P Wood; Derek Raghavan; E David Crawford Journal: N Engl J Med Date: 2003-08-28 Impact factor: 91.245
Authors: Seung Baek Hong; Nam Kyung Lee; Suk Kim; Il Wan Son; Hong Koo Ha; Ja Yoon Ku; Kyung Hwan Kim; Won Young Park Journal: J Magn Reson Imaging Date: 2020-03-27 Impact factor: 4.813
Authors: Andrea Necchi; Daniele Raggi; Andrea Gallina; Russell Madison; Maurizio Colecchia; Roberta Lucianò; Rodolfo Montironi; Patrizia Giannatempo; Elena Farè; Filippo Pederzoli; Marco Bandini; Marco Bianchi; Renzo Colombo; Giorgio Gandaglia; Nicola Fossati; Laura Marandino; Umberto Capitanio; Federico Dehò; Siraj M Ali; Jon H Chung; Jeffrey S Ross; Andrea Salonia; Alberto Briganti; Francesco Montorsi Journal: Eur Urol Date: 2019-11-08 Impact factor: 20.096
Authors: Russell E N Becker; Alexa R Meyer; Aaron Brant; Adam C Reese; Michael J Biles; Kelly T Harris; George Netto; Andres Matoso; Jean Hoffman-Censits; Noah M Hahn; Woonyoung Choi; David McConkey; Phillip M Pierorazio; Michael H Johnson; Mark P Schoenberg; Max R Kates; Alex Baras; Trinity J Bivalacqua Journal: Eur Urol Date: 2020-08-17 Impact factor: 20.096